GSK Negotiates Potential Acquisition of Nuvalent for Over $9 Billion
GSK is reportedly in discussions to acquire cancer biotech Nuvalent, a deal that could surpass $9 billion and mark one of the largest transactions for the UK drugmaker amid rising biotech M&A activity this year.